Citations

Clear

6055 citation(s) found for "Wu, Peter".

A propensity score-matched analysis comparing first-line regional, systemic, and intralesional treatments for melanoma in-transit metastases in a contemporary patient population.
Balsay-Patel, Caitlyn , Dugan, Michelle, Naqvi, Syeda Mahrukh Hussnain , Ollila, D. W., Houdt, Winan J. van, Asher, Nethanel, Snow, Hayden, Farma, Jeffrey M., Vetto, John T. , Saw, Robyn P.M., LO, S, Long, Georgina V., Ny, Lars, Akkooi, Alexander Christopher Jonathan Van, Bagge, Roger Olofsson, Zager, Jonathan S., Long, Georgina V. , Akkooi, Alexander C. J. van , Saw, Robyn P.M. , Lo, Serigne , Long, Georgina V , Lo, Serigne N , Dugan, Michelle M. , Hieken, Tina J. , Houdt, Winan J. van , Asher, Nethanel , Broman, Kristy K. , Farma, Jeffrey M. , Hui, Jane Yuet Ching , Ny, Lars , Kim, Youngchul , Bagge, Roger Olofsson , Zager, Jonathan S.

Mayo Clinic

Journal of Clinical Oncology | May 28, 2026 | Volume: 44 | Issue: 16_suppl | Pages: 9524-9524

10.1200/jco.2026.44.16_suppl.9524 Get It

9524 Background: Unresectable melanoma in-transit metastases (ITM) can pose a significant clinical challenge. Our recently published data comparing first-line treatments for ITM, isolated limb infusion or perfusion (ILI/ILP), immune checkpoint inhibitors (ICI) and intralesional talimogene laherparepvec (TVEC), found superior outcomes with TVEC. However, TVEC was used more often in patients with lower disease burden and earlier stage (IIIB vs. IIIC/D). Therefore, we sought to better investigate these differences with a propensity score-matched (PSM) analysis. Methods: A multi-institutional, international IRB- approved retrospective analysis was conducted for unresectable melanoma ITM from 2016-2022. PSM analysis comparing first-line ILI/ILP, ICI, and TVEC for was performed. Patients were matched for stage, number of ITM, anatomical site, CLND status, gender and age. Kaplan-Meier curves (OS, PFS, DMFS) and Cumulative incidence function (MSS) were used to visualize time-to-event outcomes in the PSM cohort, though both methods do not account for the matched structure. Results: 274 patients were identified, 120 female/154 male; 96 treated with ILI/ILP, 111 with ICI, and 67 with TVEC. Median follow-up was 40 months (range, 1-80). PSM was performed and identified 36 TVEC–ICI pairs and 27 TVEC–ILI pairs. These were combined resulting in a final cohort of 108 observations (45 TVEC, 36 ICI and 27 ILI). The groups were well balanced. No statistical difference was found for metastasis-free survival (DMFS), progression-free survival (PFS), melanoma-specific survival (MSS), and overall survival (OS) between treatment modalities. TVEC was associated with significant improvement in local PFS (median was 2.2 years (y) for ILI/ILP, 1.5y for ICI and not reached for TVEC, p=0.048). While not statistically significant, a clinical benefit was seen in PFS being longer for TVEC (2.1y for TVEC vs. 1.2y for ILI/ILP and 1.1y for ICI; p=0.2) and OS (not reached vs 2.9y for ILI/ILP and 5.2y for ICI; p=0.2). On mixed effect Cox regression proportional hazard model using the matched data set, there were no significant differences in any of the survival and recurrence outcomes. Conclusions: When patients are propensity-matched, there were no significant differences in first-line treatment modalities for unresectable melanoma ITM. Treatment with TVEC did result in clinically meaningful improved overall and local PFS and OS. This supports that selection of ITM therapy should incorporate an individualized approach, incorporating disease distribution, stage, burden, treatment side effects and patient priorities.
Anti–PD-1 (PD-1) monotherapy versus combination with anti–CTLA-4 for metastatic uveal melanoma (MUM) patients (pts).
Silva, Ines Esteves Domingues Pires da, Grynberg, Shirly , Forschner, Andrea , Vincent, T., Liddle, Conner, Hopkins, Sam , Steinkerchner, Megan, Khaddour, Karam , Huerta, Luis Paul Del Carpio, Win, Su, Gebhardt, Christoffer , Hans, Tasvinder Kaur, Carlino, M S, Block, Matthew S. , Menzies, A, LO, S, Long, Georgina V., Long, Georgina V. , Lo, Serigne , Long, Georgina V , Lo, Serigne N , Grynberg, Shirly , Stoff, Ronen , Ma, Vincent The-Luc , Steinkerchner, Megan S. , Weichenthal, Michael , Carpio, L.P. del , Boutros, Andrea , Carlino, Matteo S. , Menzies, Alexander M

Mayo Clinic

Journal of Clinical Oncology | May 28, 2026 | Volume: 44 | Issue: 16_suppl | Pages: 9535-9535

10.1200/jco.2026.44.16_suppl.9535 Get It

9535 Background: MUM carries a poor prognosis with few effective treatments, especially for HLA-A*02:01-negative pts. While a subset of MUM pts responds to immune checkpoint inhibitors, the comparative efficacy of IPI+PD1 versus PD1 monotherapy is unclear. This study compares objective response rate (ORR), progression-free survival (PFS), overall survival (OS), and safety between these regimens in MUM. Methods: MUM pts treated with PD1 or IPI+PD1 at 15 major melanoma centres (from Australia, Europe, United States and Israel) were included. Demographics, patient and disease characteristics, and clinical outcomes were examined. Univariate and multivariate (MVA) analyses were performed to identify clinical predictors of response and survival. Results: Of 412 MUM pts treated, 150 (36%) had PD1 and 262 (64%) received PD1+IPI. Compared to the PD1 group, PD1+IPI-treated pts were younger (64 vs. 70 years; p<0.001), had higher rate of elevated LDH (44% vs. 31%; p=0.037), and more frequently had prior treatment with tebentafusp (6.5% vs. 1.3%; p=0.031). Median follow-up from commencement of PD1+/-IPI was 4.9 years (95% CI 4.7 – 6.1). ORR was higher in IPI+PD1 group (18%) vs. PD1 (9%) (p=0.008), particularly in males (p=0.009), patients with liver metastases (p=0.018) and with lung metastases (p=0.011), with elevated LDH (p=0.047) and with no prior treatment with tebentafusp (p=0.007). PFS and OS at 1 and 2 years were numerically higher with IPI+PD1 (1- and 2-year PFS: 23% and 15%; 1- and 2-year OS: 63% and 39%) vs. PD1 (1- and 2-year PFS: 17% and 11%; 1- and 2-year OS: 54% and 36%), but these differences were not statistically significant (p>0.05). On MVA, adjusting for predefined variables (age, gender, ECOG PS, LDH, presence/absence of liver/lung metastases, prior treatment with tebentafusp), IPI+PD1 was associated with higher ORR (OR 2.71, 1.30 – 6.05; p=0.01) but not with PFS or OS compared to PD1. Presence of liver metastases (ORR [OR 0.28; 95% CI 0.13 - 0.64], PFS [HR 1.61; 95% CI 1.11 - 2.34], OS [HR 2.02; 95% CI 1.32 - 3.10]), ECOG PS≥2 (PFS [HR 1.82; 95% CI 1.07 - 3.10], OS [HR 2.24; 95% CI 1.25-4.01]), elevated LDH (PFS [HR 1.66; 95% CI 1.30 - 2.11], OS [HR 2.39; 95% CI 1.84-3.10]) and prior tebentafusp treatment (OS [HR 2.36; 95% CI 1.21-4.59]) were also independent predictors of response and/or survival. A higher percentage of pts experienced grade ≥3 immune-related adverse events (irAEs) in the IPI+PD1 group compared to the PD1 group (34% vs 13%, p<0.0001). Most pts ceased treatment due to progression (234, 57%), and more pts stopped due to toxicity in the IPI+PD1 vs. PD1 group (25% vs. 9%, p<0.0001). Conclusions: In pts with MUM, IPI+PD1 demonstrated a higher ORR but did not improve survival compared with PD1 alone. IPI+PD1 was more toxic, leading to early treatment discontinuation in one-quarter of pts. These findings may help guide treatment selection in MUM.
Initial safety and efficacy of A2B694, a logic-gated mesothelin (MSLN)–targeted Tmod chimeric antigen receptor T-cell (CAR T) therapy in patients with advanced solid tumors with HLA-A*02 loss of heterozygosity (LOH).
Molina, Julian R. , Ward, Jeffrey, Hecht, J. Randolph, Kirtane, Kedar, Marar, Rosalyn, Fankuchen, Olivia Rose, Mitchell, Jasmine, Maloney, David G. , Patel, Sandip Pravin , Dorigo, Oliver, He, Kai, Lou, Yanyan, Kundranda, Madappa N. , Xuan, Jacqueline D., Avila, Monica , Ward, Jeffrey, Kirtane, Kedar , Fankuchen, Olivia , Mitchell, Jasmine , Maus, Marcela V , Eng, Cathy , Hazim, Antonious , Dorigo, Oliver , Vu, Peter , Punekar, Salman R.

Mayo Clinic

Journal of Clinical Oncology | May 28, 2026 | Volume: 44 | Issue: 16_suppl | Pages: 8579-8579

10.1200/jco.2026.44.16_suppl.8579 Get It

8579 Background: LOH may provide a means to target tumor versus normal cells, to augment the efficacy and safety of MSLN-targeted programs (Hecht et al. JCO . 2022). A2B694 is an autologous, logic-gated, Tmod CAR T therapy designed to improve tumor selectivity and decrease toxicity by integrating an MSLN CAR activator with an HLA-A*02 blocker (Hamburger et al. Mol Imm. 2020). Methods: The first-in-human, open-label, phase 1/2 EVEREST-2 (NCT06051695) study of A2B694 in patients with recurrent/metastatic MSLN-expressing cancers with tumor-associated HLA-A*02 LOH. The prescreening study BASECAMP-1 (NCT04981119) identifies eligible patients and cryopreserves leukapheresis product. Upon progression, A2B694 is manufactured and administered after lymphodepletion. Phase 1 primary objective: evaluate the safety and tolerability of A2B694 and identify a recommended phase 2 dose. Results: As of 05 January 2026, 13 patients were enrolled: 8 women/5 men, median age 59 years, 11 non-Hispanic White/2 Hispanic with unknown race. Tumor types included colorectal (n = 4), ovarian (n = 3), pancreatic (n = 3), non–small cell lung adenocarcinoma (NSCLC), gastro-esophageal, and mesothelioma (n = 1 each). A2B694 dose level (DL) groups were: DL1: 1×10 8 cells (n = 3), DL2: 2×10 8 cells (n = 4), DL3: 4×10 8 cells (n = 5), and DL4: 6×10 8 cells plus low-dose IL-2 (n = 1). Lymphodepletion prior to administration of A2B694 was well-tolerated, with expected, transient cytopenias. The only adverse event reported in more than 1 patient was grade 3 neutropenia. One patient had grade 3 ICANS and 1 patient had grade 1 CRS. There were no dose-limiting toxicities or new safety signals after up to 17 months follow-up. All 13 patients received A2B694, were efficacy-evaluable, and had A2B694 detected post-infusion in peripheral blood. While A2B694 was not detected in tumor biopsies collected in patients treated at DL1 (0/2), all patients treated at DL2-DL4 with available biopsies (3/3) had detectable A2B694 in the tumor microenvironment. A patient with KRAS G12V /STK11 co-mutated NSCLC who had progressed on carboplatin, pemetrexed, and pembrolizumab achieved a complete response (CR) at D90 post-infusion per RECIST 1.1 by central review and had a confirmed CR at D180. In addition, PET-CT scan and ctDNA on D190 demonstrated no evidence of disease. On D243, the patient had a CNS relapse, with an ongoing non-CNS CR per RANO-BM at D284. At M12, the patient's CT showed no new findings and persistence of A2B694 in the blood was confirmed by ddPCR. Conclusions: We report the first patient with NSCLC to have a CR after CAR T. Overall, A2B694 demonstrated manageable safety and tolerability in patients with advanced solid MSLN-expressing tumors with tumor-associated HLA-A*02 LOH. The maximum tolerated dose has not been reached; dose-escalation continues. Clinical trial information: NCT06051695 .
Impactof MET amplification (amp) on telisotuzumab vedotin (Teliso-V) efficacy and safety in 2L+ non-squamous (NSQ) EGFR wild-type (WT) NSCLC with c-Met protein ov
Mansfield, Aaron Scott, Daaboul, Nathalie , Horinouchi, Hidehito, Baijal, Shobhit , Lu, Shun, Ratajczak, Christine, Öhrling, Katarina, Patel, Shilpen, Woll, Kellie, Mhaske, Pallavi, Zhang, Jianhai, Verma, Mukesh, Zhao, Weilong , Roberts-Rapp, Lisa, Zhang, Nancy, Ansell, Peter, Navas, Tony , Camidge, David Ross , Bar, Jair , Horinouchi, Hidehito , Ratajczak, Christine K. , Sun, Yan , Roberts-Rapp, Lisa A., Navas, Tony A.

Mayo Clinic

Journal of Clinical Oncology | May 28, 2026 | Volume: 44 | Issue: 16_suppl | Pages: 8524-8524

10.1200/jco.2026.44.16_suppl.8524 Get It

8524 Background: Teliso-V is a c-Met–directed antibody-drug conjugate comprising telisotuzumab and the microtubule polymerization inhibitor monomethyl auristatin E (MMAE) payload. In the Ph2 LUMINOSITY study (NCT03539536), Teliso-V showed durable responses and manageable safety (Camidge et al, JCO 2024;42:3000-11) resulting in its accelerated approval in locally advanced/metastatic NSQ NSCLC with high c-Met protein OE (3+, ≥50%), as determined by an FDA-approved test. MET amp is a negative prognostic risk factor in advanced NSCLC, frequently associated with recurrent disease. High levels of MET amp and c-Met OE are hallmarks of MET -addicted tumors. Here, we analyzed the effects of MET amp on clinical responses to Teliso-V in LUMINOSITY. Methods: MET amp was evaluated by FISH and ctDNA in baseline samples from 108 NSQ EGFR WT NSCLC pts with c-Met OE (3+, ≥25%). MET amp by FISH was defined as having focal MET amp (MET/CEP7 ≥2.0) with MET gene copy number (GCN) ≥4. MET amp (focal) by ctDNA was defined as having plasma MET GCN ≥4 with no co-amplification in CDK6 and EGFR. c-Met OE by Immunohistochemistry (IHC; SP44) was defined as 3+ tissue staining intensity in ≥25% tumor cells (high c-Met OE: 3+, ≥50%; intermediate [int] c-Met OE: 3+, 25% to 49%). Exploratory analysis of tumor response was assessed in 76 efficacy evaluable pts with c-Met OE and MET amp assay results. Results: MET amp was detected in 34% (37/108) of pts with c-Met OE (3+, ≥25%) and was enriched by c-Met levels: 22% (11/50) in pts with Int c-Met OE (3+, 25% to 49%) and 45% (26/58) in pts with high c-Met OE (3+, ≥50%). The effects of MET amp on tumor response in LUMINOSITY are shown in Table 1. The majority of c-Met OE pts (79%) with PFS ≥10 mo (n=14) had GCN ≥10 and/or c-Met IHC 3+ ≥50%. No new safety signals were reported in pts with c-Met OE and MET amp. Conclusions: MET amp is more common in pts with high c-Met OE in this retrospective subgroup analysis. Tumor activity with Teliso-V was observed regardless of MET amp status. The impact of MET amp in pts with c-Met OE will be further evaluated in ongoing Phase 3 study (NCT04928846). Teliso-V efficacy in NSQ EGFR -WT NSCLC pts with c-Met OE with or without MET amp in LUMINOSITY. Total c-Met OE(3+, ≥25%) Total c-Met OE(3+, ≥25%) Intermediate c-Met OE(3+, ≥25%-49%) Intermediate c-Met OE(3+, ≥25%-49%) High c-Met OE(3+, ≥50%) High c-Met OE(3+, ≥50%) MET amp(N) No (N=53) Yes (N=23) No (N=30) Yes (N=7) No (N=23) Yes (N=16) ORR %(95% CI) 28 (18.0, 41.6) 39 (22.2, 59.2) 23 (11.8, 40.9) 57 (25, 84.2) 35 (18.8, 55.1) 31 (14.2, 55.6) PFS,median, mo(95% CI) 5.26 (3.71, 8.11) 8.02 (4.47, 14.65) 5.32 (2.69, 8.11) 7.52 (4.47, NA) 4.17 (3.25, 8.87) 8.02 (3.06, 25.92) OS,median, mo(95% CI) 14.5 (8.18, 17.38) 13.86 (6.54, 22.24) 14.03 (3.65, 17.02) 9.79 (6.54, NA) 16.26 (5.59, 36.44) 13.86 (3.06, 30.29)
Results from a phase 2a study of atebimetinib in combination with mGnP in advanced or metastatic pancreatic cancer.
Chung, Vincent, Vincent, T., Uboha, N., Majeed, Umair, Chandra, Sunandana , Mahalingam, Devalingam, Pelster, Meredith, Pavlick, Anna C. , Ocean, Allyson J. , Ma, Barbara T., Spira, A.I., Duffy, Stephen, Henry, Jason T. , Philipovskiy, Alexander, Pant, Shubham, Chawla, Sant P. , Ahn, Daniel H., Chung, Vincent , Vu, Peter , Ma, Vincent The-Luc , Uboha, Nataliya V. , Majeed, Umair , Mahalingam, Devalingam , Johnson, Melissa L. , Pelster, Meredith S. , Botta, Gregory P. , Pant, Shubham , Ahn, Daniel H.

Mayo Clinic

Journal of Clinical Oncology | May 27, 2026 | Volume: 44 | Issue: 16_suppl | Pages: 4013-4013

10.1200/jco.2026.44.16_suppl.4013 Get It

4013 Background: Pancreatic ductal adenocarcinoma (PDAC) is driven predominantly by oncogenic KRAS signaling, yet prior attempts to target the MAPK pathway have been limited by toxicity and emergence of resistance. Atebimetinib is a next-generation, deep cyclic inhibitor (DCI) of MEK designed to achieve pulsatile pathway inhibition with improved tolerability. We report a Phase 2a cohort evaluating atebimetinib in combination with modified gemcitabine/nab-paclitaxel (mGnP) in the first-line treatment of advanced or metastatic PDAC (NCT05585320). Methods: In this multicenter, open-label, nonrandomized Phase 2a study, patients with previously untreated advanced or metastatic PDAC were eligible for participation and were treated with orally administered atebimetinib daily in combination with mGnP (modification: every other week dosing). The primary endpoint was objective response rate (ORR) per investigator assessment using RECIST 1.1 criteria in response-evaluable patients. The cohort was powered (~80%, one sided alpha 0.05) using an optimal Simon’s 2-stage design. Results: Fifty-five patients were enrolled and treated with 320 mg atebimetinib daily + mGnP. ECOG performance status was 0-1 (100%); median age was 68 years (range 42-85 years), 62% were ≥65 years, and 55% were male. No grade 5 treatment-related adverse events (AE) were observed. No AE related to atebimetinib were higher than grade 3. Grade 3 AE related to atebimetinib occurred in 29% of participants, with the most frequent being rash (5%), ALT increased (5%), and AST increased (5%). Among the 50 response-evaluable patients, best overall response (BOR) achieved were 21 PR, 21 SD, 7 PD, 1 NE. The ORR was 42%, and DCR was 84%. With a median follow-up of 10.4 months (data cutoff Jan 7, 2026), 6- and 9-month OS rates were 88% and 79%, respectively; median PFS was 8.3 months and median OS was not reached. Conclusions: Atebimetinib in combination with mGnP demonstrated favorable safety and promising efficacy compared to historic standard-of-care (SoC) GnP. 1 A phase 3 registrational trial is planned to start in mid-2026 for evaluation of atebimetinib + mGnP versus SoC GnP. 1. Von Hoff DD, Ervin T, Arena FP, et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med . 2013;369(18):1691-1703. doi:10.1056/NEJMoa1304369 (PMID: 24131140). Clinical trial information: NCT05585320 .
Health-related quality of life (HRQOL) in the phase 3 trial of standard chemotherapy alone or combined with atezolizumab as adjuvant therapy for patients with stage III deficient DNA mismatch repair (dMMR) colon cancer (Alliance A021502, ATOMIC).
Dueck, Amylou C., Fruth, Briant, Reinacher-Schick, Anke C., Peters, Walter, Behrens, Robert J. , Lieu, Christopher, Matin, Khalid , Cohen, D S, Potter, Samara L., Shergill, Ardaman , Hsu, Dennis , Arnold, Dirk, Zemla, Tyler, Gatten, Clare A., Trask, Peter, O'Reilly, Eileen M., Meyerhardt, Jeffrey A., Sinicrope, Frank A., Dueck, Amylou C. , Fruth, Briant, Reinacher-Schick, Anke C. , Peters, Walter, Lieu, Christopher, Potter, Samara L. , Frankel, Wendy L. , Arnold, Dirk , Zemla, Tyler , O’Reilly, Eileen M. , Meyerhardt, Jeffrey A. , Ou, Fang‐Shu , Sinicrope, Frank A.

Mayo Clinic

Journal of Clinical Oncology | May 27, 2026 | Volume: 44 | Issue: 16_suppl | Pages: 3626-3626

10.1200/jco.2026.44.16_suppl.3626 Get It

3626 Background: For patients (pts) with dMMR stage III colon cancer, the addition of atezolizumab (atezo) to adjuvant 5-fluorouracil, leucovorin plus oxaliplatin (mFOLFOX6) significantly improved disease-free survival in ATOMIC (NCT02912559). Here we present HRQOL data. Methods: Pts with surgically resected stage III dMMR colon cancer were randomized (1:1) to receive mFOLFOX6 + atezo (840 mg IV q2 weeks) for 12 cycles (6 months [mo]) followed by atezo monotherapy for 13 cycles (12 mo total) versus mFOLFOX6 for 12 cycles. HRQOL was an exploratory endpoint measured using the FACT-C (includes FACT-G), FACT/GOG-NTX, EQ5D-5L, and PRO-CTCAE. Optional participation was by paper surveys at trial registration, prior to treatment cycles 4 and 7, and at 6, 12, and 36 mo after registration. Mean changes from baseline (BL) were compared between treatment arms using general linear mixed models (negative mean changes indicate worsening). At 6 mo, a two-sided 95% confidence interval excluding a difference of 1.9 points (FACT/GOG-NTX) and 6 points (FACT-C Trial Outcome Index [TOI]) favoring the mFOLFOX6 arm would indicate non-inferiority of the addition of atezo. Rates of side effect bother (FACT-G item GP5) and pt-reported adverse events (AEs) by PRO-CTCAE (composite scores, baseline adjusted) were compared using Fisher’s exact tests. Results: Of 712 randomized pts, 581 (285 atezo+mFOLFOX6; 296 mFOLFOX6) consented to participate in the survey. Pts completed 2398/3021 (79%) of expected surveys across all time points (1218/1489 [82%] atezo+mFOLFOX6; 1180/1532 [77%] mFOLFOX6). The difference in mean changes from BL between arms indicated non-inferiority of the addition of atezo at 6 mo (table); differences remained small at 12 and 36 mo. No significant differences in mean changes from BL between arms were found at 6, 12, or 36 mo for any scale. At 6 mo, 16% vs 20% of pts in each arm reported at least “quite a bit” of side effect bother (p=0.34), favoring atezo. Across cycles, atezo was associated with higher rates of pt-reported itchy skin (62% vs 48%), cough (53% vs 43%), and shortness of breath (51% vs 41%) [all p<0.05]. Conclusions: Addition of atezo to mFOLFOX6 slightly increases pt-reported AEs, but its effect on HRQOL is minimal and not clinically meaningful. Results support tolerability of atezo+mFOLFOX6 as standard of care adjuvant treatment for pts with dMMR stage III colon cancer. Support: UG1CA189823, U10CA180821, U10CA180882; Genentech, a member of the Roche group; https://acknowledgments.alliancefound.org. Clinical trial information: NCT02912559 . Scale Mo Mean change from BL – atezo+mFOLFOX6 Mean change from BL – mFOLFOX6 Diff (95% CI) FACT/GOG-NTX 6 -10.0 -10.6 0.6 (-0.8, 2.1) 12 -8.0 -9.4 1.4 (-0.2, 2.9) 36 -7.2 -6.9 -0.4 (-2.1, 1.4) FACT-C TOI 6 -4.1 -2.5 -1.6 (-3.7, 0.6) 12 2.1 1.8 0.3 (-1.9, 2.6) 36 0.7 1.8 -1.1 (-3.7, 1.5)
Sources matter: Learning to evaluate large language models for oncology treatment plans and changes observed by anchoring models to an oncology-specific database.
Yost, Connor , Palumbo, Peter, Tripathi, Nikita , Callas, Bradley, Leyfman, Yan, Monick, Sarah, Sullivan, Matthew Reeves, Torri, V, Funt, Samuel A., Loaiza-Bonilla, Arturo, Yost, Connor , Sullivan, Matthew, Umemura, Yoshie , Funt, Samuel A. , Nguyen, Ryan H. , Riaz, Irbaz Bin , Loaiza‐Bonilla, Arturo

Mayo Clinic

Journal of Clinical Oncology | May 27, 2026 | Volume: 44 | Issue: 16_suppl | Pages: 1617-1617

10.1200/jco.2026.44.16_suppl.1617 Get It

1617 Background: Large language models (LLMs) are increasingly evaluated for oncology decision support, yet guideline concordance and hallucinations remain variable across cancer types and tasks. Retrieval-augmented generation (RAG) may improve safety by constraining the evidence base used during generation. Prior oncology LLM studies report discordance with guideline-based care, but few describe a reproducible health-system “vetting mechanism” that couples guideline-only retrieval with clinician-scored safety rubrics across multiple oncology domains. Methods: We assembled 316 de-identified oncology cases in a tumor-board template: medical oncology (breast, GI, GU, leukemia; n=216), gynecologic oncology (n=50), and neuro-oncology/CNS metastatic cancer (n=50). Each case was run on three systems: baseline GPT-4 (O1), NCCN-guideline anchored RAG (O2; guideline-constrained retrieval), and a literature-anchored system (OpenEvidence; O3). Oncologists independently scored outputs using a modified Generative Performance Score (mGPS; −1 to +1) combining guideline concordance with hallucination penalties; readability/rationality was scored on a 1–5 Likert scale. Inter-rater reliability was assessed (κ =.63). This workflow was designed as a pre-deployment model credentialing step for health-system governance (source policy → case bank → clinician-scored acceptance criteria). Results: Across all 316 cases (case-averaged), O2 achieved the highest mean total mGPS (0.75) compared with O1 (0.43) and O3 (0.59). In the medical oncology cohort (n=216), O2 outperformed O1 and O3 (mean mGPS 0.72 vs 0.35 and 0.54), with higher guideline concordance (0.85 vs 0.68 and 0.75) and lower hallucination penalties (−0.09 vs −0.25 and −0.19); readability was also highest for O2 (4.17 vs 3.22 and 3.86). In gynecologic oncology (n=50), O2 again performed best (mGPS 0.827) relative to O3 (0.697) and O1 (0.647). In the CNS cohort (n=50), mean composite mGPS favored O2 (0.82) over O3 (0.68) and O1 (0.55), while readability remained stable across models (3.55–3.73). Severe hallucination/unsafe recommendation rate: O1 [26%], O2 [5%], O3 [17%] (pre-specified definition; e.g., major fabricated citation or guideline-discordant harmful recommendation). Conclusions: In a 316-case, multi-domain clinician-scored evaluation, limiting retrieval to oncology guideline sources improved safety-aligned performance relative to unconstrained generation or literature-only anchoring. A guideline-constrained RAG configuration paired with clinician-scored rubrics and tail-risk reporting can serve as a practical health-system vetting mechanism for governance, re-validation, and change control of LLM decision support, including in resource-limited settings where reliable guideline-consistent recommendations are essential.
Association of drug industry payments to oncologists and use of guideline-preferred cancer treatments.
Augello, Patrick, Abdelaziz, Abdullah, Guzman, Gabrielle , Galanter, Nina, Chakraborty, Nirjhar , Klimchuk, Maria , Alsamarai, Susan, Rajkumar, S. Vincent, Bach, Peter B. , Gönen, Mithat , Mitchell, Aaron Philip , Winn, Aaron N. , Augello, Patrick , Meza, Akriti Mishra , Abdelaziz, Abdullah , Galanter, Nina , Dusetzina, Stacie B.

Mayo Clinic

Journal of Clinical Oncology | May 27, 2026 | Volume: 44 | Issue: 16_suppl | Pages: 11059-11059

10.1200/jco.2026.44.16_suppl.11059 Get It

11059 Background: Payments from the drug industry to oncologists are common and influence physicians’ prescribing decisions. However, whether payments affect the likelihood that patients receive optimal cancer treatment has not been assessed. Methods: This was a population-based cohort study. We used fee-for-service Medicare claims to identify patients with incident cancer diagnosis (new cancer diagnosis code after >= 1 year with no cancer diagnosis codes) from 2014-2020. We used National Comprehensive Cancer Network (NCCN) Guidelines to identify treatment scenarios (e.g., metastatic melanoma, stage III colon adjuvant therapy) with variation in the clinical benefit among recommended treatment options. The patient cohort corresponding to each scenario was identified using claims. We used NCCN Guidelines to identify the “optimal” treatment for each scenario (defined as the designated “preferred” treatment, with NCCN Evidence Blocks scores used for tiebreaks) at each time point across the study period. The primary outcome was whether a patient received the treatment that was, as of their diagnosis date, the optimal treatment for their cancer (vs. any non-optimal treatment). The primary exposure[s] were whether a patient’s medical oncologist received personal (“general”) payments (source: linked Open Payments data) related to 1) optimal treatment or 2) any non-optimal treatment, during the year prior to the patient’s cancer diagnosis. We fit Poisson-family generalized estimating equations, with physician-level clustering and adjustment for scenario, year, and patient characteristics, to estimate the relative risk (RR) of optimal treatment. Results: There were 14 clinical scenarios comprising 15,835 patients. There were 3,429 (21.7%) patients whose oncologist received payment for the optimal treatment, 4,891 (30.9%) for non-optimal payments, and 1,993 (12.6%) to both payment types. Oncologist receipt of payment for optimal treatment was associated with a greater likelihood (RR=1.07, 95%CI:1.01-1.13), and payment for non-optimal treatment was associated with lower likelihood (RR= 0.94, 95%CI:0.89-0.98) of patients receiving optimal treatment. Associations became stronger as payment dollar value increased; for optimal payments ≥$10,000, RR=1.26 (95%CI:1.02-1.57), and for non-optimal payments ≥$10,000, RR=0.70 (95%CI: 0.49-1.00). An estimated 41.6% of unexposed patients received optimal treatment; versus 52.6%, 29.3%, and 33.8% among patients exposed to ≥$10,000 of payments for optimal treatment only, ≥$10,000 non-optimal payments only, and ≥$10,000 of both payment types, respectively. Conclusions: Industry payments related to the optimal cancer treatment were associated with increased use of the optimal treatment. However, payments related to non-optimal treatments were more common and were associated with decreased use of optimal treatment.
Humility: The Essential Virtue Enhancing Patient Care, Education, Research, and Innovation
Rizzo, Marco, Lin, Ines, Murray, Peter, Sotereanos, Dean, Stern, Peter, Rizzo, Marco , Lin, Ines C. , Sotereanos, Dean G., Stern, Peter J.

Mayo Clinic

Journal of Bone and Joint Surgery | May 26, 2026 | Volume: 108 | Issue: 15 | Pages: 1149-1152

10.2106/jbjs.26.00381 | PMID 42189960 Get It

The word humility is derived from the Latin word humus, meaning “ground” or “soil.” Romans equated humility with being grounded. Perhaps because it contradicts our natural tendencies toward self-preservation, humility remains an often misunderstood and underappreciated virtue. It is foreign to many, especially in today’s society, which is so focused on self-promotion. However, it is truly one of the most important and powerful virtues that a person can possess and practice. Humility is a just assessment of ourselves and the world around us. It is not thinking less of oneself; rather, it is actually thinking less about oneself. In looking beyond ourselves, we can obtain an honest estimate of our limitations and what is needed to remain patient-centered. In approaching our profession with humility, we more closely honor the privileges of caring for patients, teaching others, innovating, and advancing science. The aim of this article is to show how humility nurtures our development in all aspects of medicine. A humble clinician maintains a steadfast focus on their patient, a humble educator emphasizes the learner, a humble researcher respects science through their honesty and integrity, and a humble innovator does not let pride blind them, recognizing that innovation without humility is doomed to fail. In addition to being a superpower in medicine, humility blesses us with the wisdom and gratitude that come from experiencing, living for, and working for something bigger than ourselves. Gratitude has been considered the father of all virtues, and our ability to be truly grateful requires a core of humility.
Examining burnout, work–life balance, relocation and financial stress among UK resident doctors and medical students
Rehman, Umar , Chin, Kai Jian , Kungwengwe, Garikai , Perwaiz, Ibrar, Aktar, Lahreb, Choudhury, Rozina Yasmin, Jaffee, Ally, Pereira, Mariam, Arab, Sammy, Chhatwal, Karanjot , Filson, Simon, Cavale, Naveen , Hafner, Marco , Hankir, Ahmed, Brennan, Peter, Lechner, Matt, Group, WARM Study Collaborators, Arab, Sammy , Arab, Sammy , Rehman, Umar , Perwaiz, Ibrar , Sarwar, Mohammad Sohaib , Filson, Simon A. , Hankir, Ahmed Khaldoon , Lechner, Matt

Mayo Clinic

The British Journal of Psychiatry | May 26, 2026 | Volume: No volume available | Issue: No issue available | Pages: 1-8

10.1192/bjp.2026.10666 | PMID 42187538 Get It

Background Burnout arises from prolonged, unresolved work-related stress and adversely affects professional performance and overall well-being. Resident doctors and medical students are particularly vulnerable because of the demands of balancing clinical, academic and related responsibilities. Aims This study aimed to assess self-reported burnout and related stressors among UK resident doctors and medical students, and estimate the economic impact of burnout-related absenteeism among resident doctors. Method Self-report questionnaires assessing burnout and related stressors were distributed to UK resident doctors and medical students. A total of 2793 responses were received: 1439 (51.5%) from resident doctors and 1354 (48.5%) from medical students. Economic losses from absenteeism were calculated with a human capital approach. Results Burnout was reported by 70% ( n = 1008) of resident doctors and 65.7% ( n = 889) of medical students. Notably, 56.8% ( n = 573) and 79.3% ( n = 705) of resident doctors and medical students affected by burnout, respectively, were unaware of available support services. Relocation stress (85.1% of residents and 62.6% of students), financial stress (53.9% of residents and 57.8% of students) and poor work–life balance (32.1% of residents and 20.7% of students) were commonly reported. The annual economic burden of absenteeism related to burnout among resident doctors was estimated to reach £251.5 million. Conclusions Burnout among UK resident doctors and medical students may reflect a combination of underlying factors, including financial strain, relocation stress and difficulties with work–life balance. These findings underscore the need for targeted interventions that support well-being and address financial and relocation challenges, which may, in turn, help prevent burnout and improve retention within the medical workforce. Reducing burnout and associated stressors may also help lessen its economic impact, allowing resources to be redirected towards patient care.